The use of leukodepleted blood components may reduce some adverse effects of transfusion in certain clinical situations. This review outlines the recognised effects of contaminating passenger leucocytes, the value of leukodepleted components in preventing some of these complications, methods of leukodepletion and the current recommendations for use of these components.
In recent years interest in the use of leukodepleted blood components has increased as a result of data indicating that certain adverse effects of transfusion can be reduced or prevented by transfusion of blood components depleted of leucocytes. However, which patients should receive these, what method should be employed and its timing remain quite controversial. Due to the high costs involved in providing leukodepleted components their efficacy must be established. Certainly, advocating the widespread introduction of leukodepleted components for all patients is too simplistic to be acceptable in current medical practice.
This review outlines the recognised effects of contaminating passenger leucocytes, the value of leukodepleted components in preventing some of these complications, methods of leukodepletion and the current recommendations for use of these components.
EFFECTS ASSOCIATED WITH TRANSFUSION OF LEUCOCYTES
Contaminating leucocytes have been associated with both beneficial and adverse side-effects; however, the latter are far more significant.
Beneficial effects
In the pre-cyclosporine era, it was recognised that a longer renal graft survival was seen in previously transfused than in non-transfused recipients, I and the presence of leucocytes seemed to be critical in producing the transfusion effect. The mechanism of the effect remains poorly understood. Theories to explain the beneficial effect on graft survival include inactivation of alloreactive clones by high-dose immuno-suppressive therapy, 2 induction of suppressor cells 3 and induction of anti-idiotypic antibodies. 4 Recently it has been found that graft survival was significantly improved in patients transfused with blood from donors sharing one HLA-DR antigen, compared with nontransfused patients or patients receiving blood mismatched for both HLA-DR antigens. 5 This observation may revive interest in the practice of blood transfusion before transplantation which, with the advent of cyclosporine therapy, has largely been abandoned.
A second possible beneficial effect is the graft-vsleukaemia effect exerted by passenger leucocytes in blood components. An increase in the post bone marrow transplant remission rate had earlier been claimed; 6 however, this has not been confirmed in a number of subsequent series of leukaemic patients. 7.8 
Adverse effects
Passenger leucocytes present III standard blood components have clearly been associated with a number of severe negative side-effects: (a) human leucocyte antigen (HLA)-alloimmunisation leading to the possible development of febrile non-haemolytic transfusion reactions (NHFTR) 9, 10 or immunologic refractoriness to random donor platelet transfusions, II (b) graft vs host disease (GVDH) in immunosuppressed 12 as well as immunocompetent recipients, 13 (c) transmission or reactivation of cytomegalovirus (CM V) infection 14.15 and transmission of human T cell leukaemia virus (HTLV) type 1. 16 In addition there is suggestive evidence that postoperative infection 17.18 and tumour recurrence l9 • 20 may be increased due to transfusion-induced immunosuppression. However, it remains to be established whether this is due to the presence of leucocytes or other constituents of the transfusion.
HLA ALLOIMMUNISATlON
The cellular events that result in establishment of an immune response are highly complex. The central step in the development of an immune response to foreign proteins is the activation of T helper lymphocytes (C04 positive T lymphocytes) by specific antigen presenting cells (APCs). The APCs must bear the same MHC class 11 molecule as the T helper lymphocyte to allow recognition by the lymphocyte. Activation of the T helper lymphocyte initiates a series of complex cellular interactions that result in B cell activation, antibody production and the activation of COS positive cells to become active killer cells.
However, there is evidence that in an allograft response or following transfusion, HLA antigens may not be processed and presented in the above manner. It appears that either the donor APCs can directly activate the recipient's T helper lymphocytes or the recipient's own APCs can process antigens and present them to T helper lymphocytes as above. However, the former is a more powerful mechanism than the latter. With this model it could be expected that blood components depleted of white cells would not exert an immunising effect, since functional APC-bearing class 11 molecules would be absent.
Non haemolytic febrile transfusion reactions
NHFTRs are the most frequent type of clinical sequelae of alloimmunisation-the occurrence is of the order of 1070 of all transfusions, though in the multitransfused patient can be 50070 or more. Clinically, the reaction between donor leucocytes and recipient antibody is manifest by fever, flushing, tachycardia, palpitations and in severe cases, dyspnoea and dry cough. Recurrent reactions of this type can be successfully prevented by the use of red blood cell (RBCs) from which 90070 to 95070 of the leucocytes have been removed.2i·"
Platelet refractoriness
Repeated failure to obtain a satisfactory response to platelet transfusion (refractoriness) is a major problem in the management of patients receiving multiple platelet transfusions. Between 30070 to 70070 of such patients may become refractory. 2l The main causes of refractoriness are either nonimmune platelet consumption, for example secondary to fever or sepsis, or immune related, that is the development of antibodies to platelets. HLA antibodies are the most important antibodies affecting the survival of transfused platelets and can be detected in as many as 50070 of multitransfused patients when measures are not taken to prevent their occurrence. 24 In addition, platelet-specific antibodies may also be present and occasionally they may be the only antibodies detected. Patients in whom HLA antibodies can be detected do not necessarily become clinically refractory. In addition, interestingly, of the patients who do become clinically refractory, the HLA antibodies may subsequently decline or disappear. 25 Management of patients who do become severely thrombocytopenic and are at risk of severe haemorrhage is difficult, and hence there has been much interest in assessing methods which may prevent or reduce HLA alloimmunisation.
The term criticial immunogenic leucocyte load (CILL) has been used to describe the minimum number of leucocytes needed to induce alloimmunisation. This CILL varies between patients and clinical situations. However, the risk of alloimmunisation decreases with a decreasing number of leucocytes and approaches zero when the number per transfusion falls below 1-5 x 10 6 • The currently accepted recommendations 26 for leucocyte-depleted components are < 10 6 leucocytes per platelet unit and < 5 x 10 6 leucocyte per red cell unit.
Although it has been suggested from the results of a number of studies that transfusion of leucocytedepleted blood components reduces the incidence of HLA alloimmunisation, 11.2'.26 in the studies performed up to 30070 of patients still became alloimmunised, probably due to significant numbers of residual leucoctyes in the components. In addition, many patients will already be immunised through previous pregnancy or transfusion, and therefore will not benefit from the use of leukodepleted components. Whether all patients to be multitransfused should receive leukodepleted components is therefore not yet certain. 29 A large randomised multi-institutional study (Trial to Reduce Alloimmunization to Platelets), which should address many of the questions raised by the studies done to date, is currently in progress in the United States. Leucocyte filtration and also UV-iJ irradiation of platelets will be evaluated. The latter approach is of particular interest as it potentially provides an extremely simple method of eliminating the alloimmunising effects of passenger leucocytes. At the present time, the use of leukodepleted platelets for all recipients receiving multiple platelet transfusions cannot be recommended as routine practice.
GRAFT VERSUS HOST-DISEASE (GVHO)
Transfusion-associated GVHO is due to proliferation of viable donor T lymphocytes as a response to HLA incompatibility between donor and recipient. The clinical manifestations are similar to post bone marrow transplant GVHO, though pancytopenia due to marrow /1l/ueslhesia and /nfen.si\'e Cure, ~"()1. 21, l\lo. /, Fehruary, 1993 aplasia is an added complication. The mortality may be as high as 90070. Patients with congenital immunodeficiency syndromes, premature neonates, and patients receiving high-dose immunosuppressive chemotherapy are those principally at risk. Of concern recently there have been more reports of post transfusion GVDH in immunocompetent patients such as following cardiac bypass. 13, 30 , Important in these cases is that in most instances patients had received fresh blood components given by close relatives. Partial haplotype compatability has therefore been possible.
Theoretically, GVHD can be prevented by either removal or inactivation of leucocytes. So far there is no clincial evidence to show that GVHD can be prevented using leukodepleted components. Animal studies have revealed that GVHD can be induced by transfusion of 1 x 10 7 leucocytes per kg. Despite the fact that the number of leucocytes in leukodepleted red cells remains below this threshold, it is not recommended for this purpose. Currently irradiation of components is the method of choice and is recommended for all immunodeficient recipients and blood transfusion from first-degree relatives.
PREVENTION OF TRANSMISSION OF INFECTION
A number of viruses may be present within leucocytes and therefore be transmitted by transfusion of standard components. The principle one of concern is CMV. Two other viruses, Epstein Barr virus (EBV) and human T cellleukemia virus type 1 (HTLV-l), are also transmitted by infected leucocytes. EBV infection associated with blood transfusion is not a major problem as most recipients are immune to EBV and protective antibodies may be passively acquired if blood components from several donations are transfused. Prevention of EBV by donor testing or leukodepletion is therefore not advocated. HT LV-l is a virus which is associated with the clinical entities of adult T cell leukaemia and tropical spastic paraparesis. Transmission through transfusion is recognised and screening donors for HTLV-l antibodies has been shown to be effective in prevention of infection. 16 In areas of the world where there is high seroprevalence, such as Japan, screening of all donors is currently performed. In Australia donors with contact in at-risk areas are selectively screened. Leukodepletion of components to prevent HTLV transmission, although a potential option, is not currently advocated.
Post Transfusion CMV Infection
CMV infection transmitted by blood transfusion may cause an infectious mononucleosis-like syndrome in immunocompetent patients, but is usually asympto-Anaesthesia and Intensive Care, Vol. 21, No, I, February, 1993 matic and no preventive measures are required. However, serious complications may occur in immunocompromised patients such as transplant recipients and low birth weight infants. Screening of donations to provide CMV-negative components for such at-risk patients is currently performed. However, as the seroprevalence of CMV in some donor populations may be up to 50%, provision of sufficient seronegative components may be difficult. As there is considerable evidence that leucocytes are a site of latent CMV infection, leukodepletion has been advocated as an effective alternative to prevent transfusion-associated infection. Recent studies 31.32 have shown that the use of leukodepleted blood components can successfully prevent CMV infection in neonates. However, these should be interpreted with caution, as what is effective for neonates who receive only small-volume transfusions might not be as successful for at-risk adult patients. A multicentre prospective study currently in progress in the United States should determine whether leukodepletion of components will be as effective in the prevention of CMV infection in immunocompromised adults.
IMMUNOSUPPRESSION BY TRANSFUSION
Awareness of the immunosuppressive effects of transfusion has generated concern regarding possible hazards to transfused patients. The two primary areas of concern are in the detection and destruction of malignant cells and defence against infectious organisms. With regard to the effect of transfusions on malignancy, to date data for humans is based only on retrospective analysis. A review of the available evidence by Tartter and Francis 20 concluded that five of the reviewed studies reported a statistically significant relationship; in three this was equivocal and three reported no relationship.
With regard to the relationship between transfusion and infection, studies including one prospective analysis 1718,33 have shown the effects of transfusions to be detrimental with an increase in postoperative infection.
The evidence for transfusion-induced immunosuppression is therefore very worrying; however, which constituent(s) of the transfusion are responsible for this potential effect has yet to be definitely determined. Results of prospective studies already underway will help to provide answers including whether, and if so to what extent, leukodepletion of blood and components may avert the adverse effects.
METHODS FOR LEUCOCYTE DEPLETION
The technology by which leucocyte-depleted components are prepared has progressed rapidly from centrifugation, washing, freezing and thawing in the 1970s to the development in the 1980s of specialised filters able to remove about 90070 to 99070 of leucocytes. Further developments have made available selective adsorption filters that can be used at the bedside or in the laboratory, able to remove 3 log of leucocytes, or a 99.9070 reduction, leaving about 10 6 residual leucocytes. Even more efficient filters with 6 to 7 log leucocyte reduction are already being trialled. J. It is recognised that filtration is the simplest and most efficient method for preparing leukodepleted components. The principal debates now concern which patients should receive these components, and also, more recently, what is the optimum timing of filtration. 35 Leucocyte reduction by filtration at the time of component preparation is in many ways preferable to the use of filters at the bedside; it minimises misuse of filters by untrained staff, provides ability to quality control the performance of filtration and provides a readily available supply of leukodepleted components. Other potential advantages of this socalled prestorage leukodepletion are related to the hypothesis that products of leucocyte metabolism or leucocyte degeneration are potentially injurious to red cells or platelets during their storage. However, for the most part, studies have not shown significant differences between standard and prestorage leukodepleted components in their metabolic parameters during storage,"·" nor that platelet function or posttransfusion platelet survival is improved by prestorage leukodepletion. 38 It had also been suggested that prestorage leucocyte removal may be a more effective means of preventing HLA alloimmunisation, but this awaits further research.
A further interesting question related to the timing of leukodepletion has been more recently addressed. Does depleting blood components of leucocytes shortly after collection reduce the bactericidal properties of blood and thus facilitate the growth of any bacteria contaminating the unit? If leucocytes are important in eliminating bacterial organisms from blood components, especially in the first few hours of storage, the increasing use of these leukodepleted components may be detrimental to the safety of transfusion. Conflicting results, largely due to major differences in experimental protocol, have been obtained from the limited numbers of studies available to date. "I.'" However, in the studies performed which best reflect actual clinical conditions, in no case was bacterial prolifera-tion enhanced in units filtered shortly after collection, and in some situations growth was actually reduced or inhibited.
Therefore at the present time there is not strong supportive evidence that prestorage leukodepletion carries a significant medical advantage over the use of bedside filtration to provide leukodepleted components. Only if the indications for transfusion of leukodepleted blood components broaden to include nearly all transfusion recipients, or if the unit cost of filters designed for leukodepletion during component preparation were to drop significantly, would leukodepletion prior to storage become cost-effective for routine practice.
RECOMMENDATIONS FOR THE USE OF LEUKODEPLETED COMPONENTS
The most recent forum at which the various issues related to leukodepletion were discussed was at the American Association of Blood Banks National Conference on Leucocyte Reduction and Blood Component Therapy, March 1992. I n summary the recommendations for use of leukodepleted components concluded as follows: (a) to prevent recurrent NHFTR reduce leucocytes in RBCs to less than 5 x 10 8 , (b) to prevent or delay alloimmunisation to leucocyte antigens in patients receiving long term transfusion support, reduce leucocytes in RBCs to less than 5 x 10 6 , (c) the prevention of refractoriness to platelets, recurrent febrile reactions to platelets and CMV infection are still under review, (d) leucocyte reduction is not indicated currently to prevent GVHD, acute lung injury due to donor anti-leucocyte antibodies, reactions or alloimmunisation in patients with limited transfusion exposures or for acellular components.
Many unanswered questions regarding leukodepletion remain. Clinical trials should now focus on the patient groups in whom the possible clinical benefits may warrant the additional costs incurred with effective leukodepletion of blood components.
